Skip to main content

Regencell Bioscience Holdings Ltd

corporate_fare Company Profile

Regencell Bioscience Holdings Ltd

RGC·NASDAQ·Life Sciences·CIK 0001829667

Regencell Bioscience Holdings Ltd is focused on developing and commercializing a natural and holistic treatment for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The company aims to commercialize a Traditional Chinese Medicine (TCM) formula, initially in Hong Kong, and then globally. This TCM formula has been utilized by a TCM Practitioner for over 30 years in treating ADHD and ASD patients. Regencell Bioscience Holdings Ltd has completed its first research study with the TCM Practitioner and has a standardized TCM formula candidate under development for ADHD and ASD patients. The company commenced its second efficacy trial using this standardized TCM formula candidate in August 2021. The company plans to conduct further investigation and research into the application of the TCM base formula for other neurological illnesses, disorders, and degeneration. Commercialization of the standardized TCM formula will begin with the establishment of a specialized sales and marketing organization, initially in Hong Kong, following the receipt of necessary approvals from Hong Kong regulatory agencies. According to the Centers for Disease Control and Prevention (CDC), ADHD is a common neurodevelopmental disorder of childhood, often diagnosed in childhood and persisting into adulthood.

Regencell Bioscience Holdings Ltd (NASDAQ:RGC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for RGC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-07, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for RGC spans 20-F, 424B5, 6-K.

Recent high-impact activity:

  • Regencell FY2026: Net Loss Triples to $11.7M; Auditor Flags Material Weaknesses
  • Regencell Bioscience Hit With Class Action Lawsuit Alleging Market Manipulation, DOJ Probe
  • Regencell Bioscience Finalizes $20M Direct Offering at 27% Discount
  • Regencell Bioscience Finalizes $20M Direct Offering at 25% Discount with Institutional Investor
  • Regencell Bioscience Secures $20M in Deeply Discounted Offering

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$11.7M
Diluted EPS
-$2.37
Op. Cash Flow
-$7.7M
Operating Income
-$11.72M
Cash & Equivalents
$14.19M
Debt / Equity
0.00×
Shares Outstanding
495.88M sh
Source: 20-F · filed 2026-10-07 · accession 0001213900-26-107581

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 349,507 shares in RGC as of the October 30, 2026 settlement, a 20.7% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 48.8% of RGC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)349,507 shares as of October 30, 2026
Change vs prior period▼ 20.7%
Days to cover1.00 at avg daily volume of 372,347
Daily short volume (FINRA facilities)48.8% of 58,918 shares on November 20, 2026
5-day average short volume53.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

RGC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with R →
$4.18
52-week range · as of 2026-10-07 $4.18 – $69
Market cap
$2.07B
Volume
111.1K (0.4× avg)
3-mo avg 313.8K
Live data · 2026-11-22 06:00 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RGC - Latest Insights

RGC
Oct 07, 2026, 4:15 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $7.11
Real-time Price: $4.18 info
Change: -$2.93 (-41%) info
Market Cap: $2.073B info
RGC
May 21, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $27.60
Real-time Price: $4.18 info
Change: -$23.42 (-85%) info
Market Cap: $2.073B info
RGC
May 19, 2026, 5:10 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.00
Real-time Price: $4.18 info
Change: -$22.82 (-85%) info
Market Cap: $2.073B info
RGC
May 19, 2026, 4:31 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $27.00
Real-time Price: $4.18 info
Change: -$22.82 (-85%) info
Market Cap: $2.073B info
RGC
May 19, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $27.31
Real-time Price: $4.18 info
Change: -$23.13 (-85%) info
Market Cap: $2.073B info
RGC
May 08, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $29.28
Real-time Price: $4.18 info
Change: -$25.10 (-86%) info
Market Cap: $2.073B info
RGC
Apr 17, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $28.78
Real-time Price: $4.18 info
Change: -$24.60 (-85%) info
Market Cap: $2.073B info
RGC
Mar 30, 2026, 7:18 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $25.50
Real-time Price: $4.18 info
Change: -$21.32 (-84%) info
Market Cap: $2.073B info
RGC
Mar 30, 2026, 6:41 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $25.50
Real-time Price: $4.18 info
Change: -$21.32 (-84%) info
Market Cap: $2.073B info
RGC
Feb 13, 2026, 9:17 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $31.00
Real-time Price: $4.18 info
Change: -$26.82 (-87%) info
Market Cap: $2.073B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets